Pharmaceuticals
Metabolon Launches New Liver Fibrosis and Kidney Function Discovery Panels to Reveal Disease Mechanisms and Facilitate Research
Metabolon's newest panels help academic and commercial researchers reveal complex biological insights about liver fibrosis and kidney dysfunction MORRISVILLE, N.C., Oct. 12, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of lif...
2023-10-12 19:57
1870
Ascletis Announces Poster Presentation of Phase II Study Topline Results of FASN Inhibitor ASC40 for Treatment of Acne at EADV Congress 2023
HANGZHOU and SHAOXING, China, Oct. 11, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of Phase II study topline results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the European Academy of Der...
2023-10-11 08:10
3920
SAFETYscan47: A Valuable Component in Revolutionizing Chemical Risk Assessments for Global Health and Safety
SAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- Eurofins Discovery, an industry-leading provider of products and services for drug discovery research, today announced its SAFETYscan®47 platform as a New Approach Methodology (NAM), part of a standardized framework aiming to revolutionize chemical risk a...
2023-10-10 23:10
2985
Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer
-- STX-721 is characterized by high selectivity and a potentially best-in-class profile -- -- Scorpion's second program to enter clinical development this year -- -- One of two EGFR programs being developed with Pierre Fabre Laboratories -- BOSTON and CASTRES, France, Oct. 10, 2023 /PRNewswire/...
2023-10-10 18:00
2152
AffaMed Technologies Announces Licensing of EVOLUX®- a novel extended monofocal intraocular lens (IOL) designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL
Expands Portfolio of Cataract Surgery Solutions for Patients in Greater China to New Extended Monofocal Segment AffaMed Therapeutics and SIFI Leadership Celebrate Strong Progress of the AffaMed Technologies Joint-Venture BEIJING, Oct. 10, 2023 /PRNewswire/ -- AffaMed Technologies ("AffaMed"), a ...
2023-10-10 09:00
4440
Kaneka Files Patent Infringement Lawsuit Against CoCrystal
TOKYO, Oct. 10, 2023 /PRNewswire/ -- On October 5, 2023, Kaneka Corporation filed a lawsuit inthe United States District Court for the Eastern District of New York against Cocrystal Technology Co. Ltd. and Cocrystal Health Industry Co. Ltd. (collectively "CoCrystal") seeking an injunction and mon...
2023-10-10 03:47
4146
Innovent Announces First Patient Dosed in the Phase 3 Clinical Study (STAR) of Efdamrofusp Alfa (IBI302), a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Neovascular Age-related Macular Degeneration
ROCKVILLE, Md. and SUZHOU, China, Oct. 9, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...
2023-10-09 08:00
7395
Xinhua Silk Road: Xinhua-Hengshan Astragalus Membranaceus Market Index unveiled in China's Shanxi
BEIJING, Oct. 8, 2023 /PRNewswire/ -- The Xinhua-Hengshan Astragalus
Membranaceus Market Index was recently unveiled in Hunyuan County, northChina's
Shanxi Province.
2023-10-08 10:02
7053
Everest Medicines' Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023
SHANGHAI, Oct. 5, 2023 /PRNewswire/ -- Everest Medicines' (HKEX 1952.HK, "Everest", or the "Company") partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") presented new biomarker and subgroup analyses from Nefecon®'s Phase 3 NefIgArd study in both posters and ...
2023-10-05 07:33
3706
Amcor's AmSky™ and AmPrima™ earn Walmart's 'Circular Connector' seal of approval
ZURICH, Oct. 4, 2023 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX: AMC), a global
leader in developing and producing responsible packaging solutions, has been
recognized for itsAmSky™
2023-10-04 23:55
6786
Large-scale proteomics in population-based studies from UK and Iceland
REYKJAVIK, Iceland, Oct. 4, 2023 /PRNewswire/ -- In a paper released today, deCODE Genetics' scientists shared their findings from a plasma proteomics study performed using affinity-based methods. They analyzed the proteins in the context of diseases and diversity in the sequence of the genome an...
2023-10-04 23:00
3734
Kensing to Acquire AOM
Acquisition expands Kensing's Natural Vitamin E and phytosterols product offerings. KANKAKEE, Ill., Oct. 4, 2023 /PRNewswire/ -- Kensing, LLC ("Kensing" or the "Company"), a leading manufacturer of Natural Vitamin E, Plant Sterols and high-purity surfactants, and a portfolio company owned by an ...
2023-10-04 21:00
5083
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients
Osemitamab (TST001) on Track to Become a Global Therapy that Elevates the Current Standard of Care for HER2-Negative G/GEJ Adenocarcinoma PRINCETON, N.J. and SUZHOU, China, Oct. 4, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical co...
2023-10-04 08:00
3748
Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
* This Emergency Use Authorization and CDC recommendation makes Novavax's vaccine the only protein-based non-mRNA COVID vaccine option in the U.S. * Novavax expects doses will be available in thousands of locations across the U.S. in the coming days, including CVS Pharmacy and Rite Aid * Fin...
2023-10-04 04:25
5836
DrinkAid Marks Its Third Anniversary with an Exclusive Partnership with Singapore's Top Artistic Talent -- Tobyato, Jaeyelle, and JONT
SINGAPORE, Oct. 3, 2023 /PRNewswire/ -- DrinkAid, Singapore's pioneering health supplement brand that alleviates the side effects of alcohol, marks its third anniversary with an exclusive partnership withSingapore's top artistic talent — Tobyato, Jaeyelle, and JONT. The limited edition boxes, r...
2023-10-03 09:00
3614
Cambrex Completes $38 Million Capacity Expansion in High Point, North Carolina
EAST RUTHERFORD, N.J, Oct. 2, 2023 /PRNewswire/ -- Cambrex today announced the completion of its$38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility inHigh Point, North Carolina. This expansion doubles the facility's manufacturing capa...
2023-10-02 20:51
2989
China Review Studio and Chinese Red Cross Foundation Release "Generation Vax" Documentary for Broadcast Internationally
The documentary outlines China's contribution to vaccine science, research, and production since the COVID-19 pandemic and includes a call for science and infectious disease research to be borderless. BEIJING, Oct. 2, 2023 /PRNewswire/ -- China Review Studio, in collaboration with Chinese R...
2023-10-02 15:00
3693
MedAlliance Acquired by Cordis for USD 1.135 Billion
GENEVA, Oct. 2, 2023 /PRNewswire/ -- Swiss-based medical technology company MedAlliance has been acquired by Cordis for a 2022 investment of$35M and a 2023 upfront closing payment of$200M, together with regulatory achievement milestones of up to$125M and commercial milestones of up to $775M throu...
2023-10-02 11:44
3244
Rimegepant is Now Available in Hong Kong, the First Market in Asia, for Migraine Management
HONG KONG, Sept. 29, 2023 /PRNewswire/ -- Pfizer announced the availability of Rimegepant inHong Kong, the first market in Asia, a calcitonin gene-related peptide (CGRP) receptor antagonist for migraine management.[1],[2] There are approximately 12.5% of people living with migraine inHong Kong[3]...
2023-09-29 17:03
3768
Ascletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure
HANGZHOU and SHAOXING, China, Sept. 29, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces positive interim data from the Phase IIb expansion cohort (the "Expansion Cohort") of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) for functional cure of ch...
2023-09-29 08:10
4203
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 293 media titles]
2026-09-18 16:29Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
Tetra Pak and Soy Excellence Center Asia Host Regional Soy Food and Beverage Programme in Thailand
[Picked up by 268 media titles]
2026-09-18 11:51
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
Most Read
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
2026-09-15 11:00
8684
QIVIKA to Launch Smart Scope on Kickstarter, Bringing a Professional Long-Range Experience to Day-and-Night Exploration
2026-09-12 09:00
7954
Temporal Raises $550 Million in Series E Round: NYSE Content Update
2026-09-14 21:14
7116
